Study on the Safety and Effectiveness of Relatlimab and Nivolumab in Children and Young Adults with Hodgkin and Non-Hodgkin Lymphoma

Sponsor: Bristol-Myers Squibb

Sponsor score: 60
Inactive

ClinicalTrials ID:NCT05255601

Provider View

This clinical trial is testing the safety and effectiveness of two drugs, relatlimab and nivolumab, in children and young adults with certain types of Hodgkin and Non-Hodgkin Lymphoma that have not responded to previous treatments.

Patient Parameters

Program Overview

The aim of this study is to evaluate how safe and effective the combination of relatlimab and nivolumab is for children and young adults who have Hodgkin or Non-Hodgkin Lymphoma that has come back or did not respond to earlier treatments. Researchers will also measure how the drugs are processed in the body and their initial effectiveness in treating these cancers.

Eligibility Criteria

Inclusion Criteria

  • Have a confirmed diagnosis of high-risk Hodgkin Lymphoma that has returned or not responded to initial treatments, before undergoing more intensive therapies like high-dose chemotherapy or stem cell transplant.
  • Have a confirmed diagnosis of Non-Hodgkin Lymphoma that has not responded to or has returned after second-line treatments. This includes specific types like primary mediastinal B-cell lymphoma, diffuse large B-cell lymphoma, mediastinal gray zone lymphoma, anaplastic large cell lymphoma, or peripheral T-cell lymphoma.
  • Must have measurable disease that shows up on PET scans for both Hodgkin and Non-Hodgkin Lymphoma groups.

Exclusion Criteria

  • Have aggressive types of B-cell lymphomas such as Burkitt lymphoma, lymphoblastic lymphoma, or NK/T-cell lymphoma/leukemia.
  • Have lymphoma that started in or spread to the brain or spinal cord.
  • Have previously been treated with certain immune therapies targeting T-cell pathways, except for anti-PD(L)-1 therapies.
  • Have received treatments targeting the LAG-3 protein.
  • Have undergone a stem cell transplant from their own cells or a bone marrow transplant from a donor.
  • Other specific criteria as defined by the study protocol.

Get This Program In Your Inbox

Receive detailed information about this treatment opportunity to review with your healthcare provider.